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Background: Matrix metalloproteinases (MMPs) are one of the major classes of proteolytic enzymes involved in
tumor invasion and metastasis and are inhibited by naturally occurring tissue inhibitors of metalloproteinases
(TIMPs). {AU Query: Please verify that corrections made to previous sentence did not alter intended meaning}. In
this study, we examined the expression of MMP-2, MMP-9, membrane-type 1 (MT1)-MMP, TIMP-1, and TIMP-2 in
renal tissue samples of renal cell cancer and examined the correlation between their expression and
clinicopathological parameters.
Methods: Renal tissue samples from 76 patients with renal cell carcinoma were available for this study. To
determine the expression of MMP-2, MMP-9, MT1-MMP, TIMP-1, and TIMP-2, semi-quantitative reverse
transcriptase-polymerase chain reaction (RT-PCR) was carried out on tumor and normal tissues.
Results: Mean MMP-2, MMP-9, MT1-MMP, TIMP-1, and TIMP-2 mRNA expression in the renal cell carcinomas was
significantly higher than in the normal renal tissue (P <0.05). The RT-PCR data of MMP-2, MMP-9, MT1-MMP, TIMP-1,
and TIMP-2 did not show any significant correlation with tumor type or pathologic grade of renal cell carcinoma.
MMP-2, MMP-9 and MT1-MMP mRNA expression increased significantly with the TNM stage of the tumor.
Conclusions: Mean MMP-2, MMP-9, MT1-MMP, TIMP-1, and TIMP-2 mRNA expression in the renal cell carcinomas
was significantly higher than in the normal renal tissue.
Keywords: Matrix metalloproteinase, Tissue inhibitor of metalloproteinase, Semi-quantitative RT-PCR, Renal cell
carcinomaBackground
Metastasis of renal cell carcinoma cells depends on some
factors that are only partly understood: proteolysis, cel-
lular attachment, angiogenesis, migration through the
barrier into secondary sites, and colonization and prolif-
eration in distant organs [1]. Proteolytic degradation of
the basement membrane is a fundamental aspect of can-
cer development and a key event in the regulation of
tumor proliferation and metastasis [2]. The invasion of
the basement membrane proceeds through a series of
discrete steps [3]. The matrix degradation in the base-
ment membrane is closely related to activities of various
subtypes of matrix metalloproteinases (MMPs) and the* Correspondence: hljhrbqzk@163.com
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reproduction in any medium, provided the orcorresponding tissue inhibitors of matrix metalloprotei-
nase (TIMPs).
MMPs are secreted as inactive pre-enzymes and are
transformed into active forms after cleavage of a propep-
tide domain of the molecule [4]. On the basis of their
structure, cell localization, and substrate specificity, the
more than 20 human MMPs are divided into several
groups such as collagenases, gelatinases, stromelysins,
and membrane-type MMPs (MT-MMPs) [5]. Among the
MMPs, MMP-2 and MMP-9 have been the focus of at-
tention in connection with cancer metastasis because of
their ability to degrade type IV collagen, a major con-
stituent of the vascular basement membrane [6]. MT1-
MMP was the first member of the MT-MMP family to
be discovered, since it is tethered to the plasma mem-
brane [7]. The expression of MT1-MMP has beend. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Oligonucleotide primers sequences for mRNA
amplification
Direction Primer sequence Fragment
size (bp)
MMP-2 Sense ACCTGGATGCCGTCGTGGAC 448
Antisense TGTGGCAGCACCAGGGCAGC
MMP-9 Sense CGCTGGGCTTAGATCATTCC 460
Antisense TTGTCGGCGATAAGGAAGG
MT1-MMP Sense TGACGGGAACTTTGACACC 262
Antisense CAGCTCCTTAATGTGCTTGG
TIMP-1 Sense GGGCTTCACCAAGACCTA 280
Antisense GAAGAAAGATGGGAGTGGG
TIMP-2 Sense CCAAAGCGGTCAGTGAGA 421
Antisense TGGTGCCCGTTGATGTTC
β-actin Sense AAGATGACCCAGATCATGTTTGAG 648
Antisense AGGAGGAGCAATGATCTTGATCTT
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surface [8].
MMP-2 is an important enzyme of the MMP family,
which is able to degrade collagen IV, a basic component of
constitutive basement membranes [9]. The activation and
enzymatic activity of MMP-2 is regulated by TIMP-2 [10].
MMP-2 has been considered essential for metastasizing
tumor cells. In this context, evaluation of MMP-2 expres-
sion in lung and colon cancer appears to be a useful prog-
nostic indicator [11,12]. Recent studies have reported an
alternative function of TIMP-1, that is, as a growth factor;
it is highly homologous with erythroid-potentiating activ-
ity, which is an autocrine growth factor for the erythroid
leukemia cell line K562 [13]. Moreover, TIMP-1 also
shares homology with a fibroblast elongation factor that is
secreted from colon carcinoma cells and that stimulates
tumor cell proliferation [14]. TIMP-1 RNA levels are
higher in primary colorectal carcinomas with distant me-
tastasis than in those without metastasis [15], and the ex-
pression of TIMPs increases with the advance of the
neoplastic process [16].
The expression and involvement of several MMPs and
TIMPs in human renal cell carcinoma have been deter-
mined in several studies. However, the studies showed
relatively conflicting results about their contribution to
the clinicopathological findings and prognosis of the
patients with renal cell carcinoma. In the present study,
we examined the expression of MMP-2, MMP-9, MT1-
MMP, TIMP-1, and TIMP-2 mRNA in human renal cell
carcinoma tissues by a reverse transcriptase-polymerase
chain reaction (RT-PCR) assay and examined the correl-




Renal tissue samples from 76 patients (45 men and 31
women) with renal cell carcinoma, for whom clinical
and histopathological data concerning the patients and
carcinomas were available, were analyzed. Renal tissue
samples were obtained from cancerous and non-
cancerous parts of the same kidney, which had been sur-
gically removed by radical nephrectomy. Tumors were
graded according to Fuhrman’s system [17] and staged
according to TNM criteria [18]. For statistical evalua-
tions, grade 1 and 2 tumors were considered as low
grade and grade 3 and 4 as high grade. Similarly, stage 3
and 4 tumors were considered in the advanced stage cat-
egory. Four patients at the time of diagnosis {AU Query:
Is this an acceptable term? Or do you mean at the time
of diagnosis?} already had a metastatic tumor. The tumor
and normal tissue samples were snap-frozen in liquid ni-
trogen immediately after surgical removal and stored at
−80°C for RNA extraction. Mean age of the patients was61.3 ± 13.5 years, ranging from 28 to 84 years. Informed
consent had been obtained, and the Ethics Committee of
Harbin Medical University approved this study.
RNA extraction and reverse transcriptase polymerase
chain reaction
Total RNA was extracted from renal tissue samples
using ISOGEN (Nippon Gene, Toyama, Japan). The
amount and purity of the extracted RNA was deter-
mined by spectrophotometry. The cDNA was synthe-
sized with 5 μg of total RNA and oligo dT primer. The
cDNA was amplified using primers specific for the
MMP-2, MMP-9, MT1-MMP, TIMP-1 and TIMP-2
genes, or for the β-actin gene, which was used as a con-
trol (Table 1). PCR conditions for MMP-2 and β-actin
amplification were 30 cycles at 94°C for 30 seconds, 62°C
for 30 seconds, and 72°C for 30 seconds, followed by incu-
bation at 72°C for 5 minutes. PCR conditions for MT1-
MMP amplification were 30 cycles at 94°C for 1 minute,
60°C for 1 minute, and 72°C for 1 minute, followed by
incubation at 72°C for 5 minutes. PCR conditions for
MMP-9, TIMP-1 and TIMP-2 amplification were 30 cycles
of 94°C for 1 minute, 56°C for 30 seconds, and 72°C for
1 minute, followed by incubation at 72°C for 5 minutes.
The PCR mixture was amplified using a GeneAmp PCR
System 9600 (PerkinElmer, Wellesley, MA, USA).
Amplified products (10 μl) were identified by electro-
phoresis of the PCR products on a 1.5% agarose gel con-
taining ethidium bromide and ultraviolet illumination.
The housekeeping gene β-actin was used as a control
and for semi-quantitative analysis of the MMP-2, MMP-9,
MT1-MMP, TIMP-1, and TIMP-2. A negative control,
with H2O instead of cDNA, was also used. The levels of
gene transcripts were quantified as the ratio of the inten-
sity of the target gene to the intensity of β-actin.
Table 2 Clinicopathological features of 76 renal cell
carcinomas
Variables Renal cell carcinoma (n = 76)










Grade 1 and 2 57
Grade 3 and 4 19
Tumor stage
Stage 1 and 2 52
Stage 3 and 4 24
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The results were expressed as means ± the standard de-
viation. The expression of MMP-2, MMP-9, MT1-MMP,
TIMP-1, and TIMP-2 were performed with Student’s t-test.
The association between the clinicopathological vari-
ables and the expression of MMP-2, MMP-9, MT1-Figure 1 Reverse transcriptase polymerase chain reaction analysis of
tissues. N, normal tissue; T, tumor tissue; MMP, matrix metalloproteinase; M
inhibitor of matrix metalloproteinase.MMP, TIMP-1, and TIMP-2 was also analyzed using
Student’s t-test. The accepted level of significance was P
<0.05. All data analysis was performed using the SPSS
for Windows, Version 10.0 software package (SPSS Inc,
Chicago, IL).Results
Of the 76 renal cell carcinomas, there were 59 clear cell,
11 papillary, 4 chromophobe, and 2 sarcomatoid carcin-
omas. (Table 2) There were 45 male (59.2%) and 31 fe-
male (40.8%) patients aged from 28 to 84 years with a
mean age of 61.3 ± 13.5 years. The tumors were categor-
ized as grade 1 and 2 in 57 (75%) cases and grade 3 and
4 in 19 (25%) cases; and stage 1 and 2 in 52 (68%) cases
and stage 3 and 4 in 24 (32%) cases.
Expression of MMPs and TIMPs could be detected in
all renal tissue samples, and their levels varied among
cases. The mRNA expression of the proteolytic enzymes
MMP-2, MMP-9, MT1-MMP, TIMP-1, and TIMP-2 is
shown in Figure 1. A comparison of the relative amounts
of MMP-2, MMP-9, MT1-MMP, TIMP-1, and TIMP-2
mRNAs in renal cell carcinomas and normal renal tissue
is shown in Table 3. Mean MMP-2, MMP-9, MT1-MMP,
TIMP-1, and TIMP-2 mRNA expression in the renal cell
carcinomas was significantly higher than in the normal
renal tissue (P <0.05).mRNA expression for proteolytic enzymes in normal and tumor
T1-MMP, membrane-type 1 matrix metalloproteinase; TIMP, tissue
Table 5 Expression of matrix metalloproteinases (MMPs)
and tissue inhibitors of metalloproteinases (TIMPs) by
tumor stage
Tumor Stage
Low stage Advanced stage P value
MMP-2 0.652 ± 0.043 0.901 ± 0.068 P <0.05
MMP-9 0.604 ± 0.035 0.923 ± 0.077 P <0.05
MT1-MMP 0.320 ± 0.038 0.749 ± 0.080 P <0.05
TIMP-1 0.353 ± 0.046 0.412 ± 0.051 NS
TIMP-2 0.373 ± 0.029 0.402 ± 0.042 NS
NS, not significant.
Table 3 Expression of matrix metalloproteinases (MMPs)
and tissue inhibitors of metalloproteinases (TIMPs)
Tumor tissue Normal tissue P value
MMP-2 0.732 ± 0.067 0.342 ± 0.021 <0.05
MMP-9 0.701 ± 0.089 0.238 ± 0.019 <0.01
MT1-MMP 0.460 ± 0.034 0.191 ± 0.022 <0.01
TIMP-1 0.375 ± 0.042 0.153 ± 0.020 <0.05
TIMP-2 0.386 ± 0.015 0.234 ± 0.013 <0.05
Qiao et al. World Journal of Surgical Oncology 2013, 11:1 Page 4 of 6
http://www.wjso.com/content/11/1/1In terms of pathologic grade of renal cell carcinoma,
the differences in MMP-2, MMP-9, MT1-MMP, TIMP-
1, and TIMP-2 mRNA expression levels were not signifi-
cant. Similarly, MMP-2, MMP-9, MT1-MMP, TIMP-1,
and TIMP-2 mRNA expression did not differ signifi-
cantly in relation to tumor type of renal cell carcinoma
(Table 4). In terms of tumor stage of renal cell carcin-
oma, the differences in MMP-2, MMP-9 and MT1-
MMP mRNA expression levels were significant (Table 5).
MMP-2, MMP-9 and MT1-MMP mRNA expression
increased significantly with the TNM stage of the tumor.
Discussion
Tumor growth, invasion, and metastasis is a multistep
process that is facilitated by the proteolytic degradation
of components of the extracellular matrix (ECM) and
basement membrane. The role of MMPs in this process
has been firmly established based on numerous previ-
ously published experimental and clinical studies. In the
present study, mean MMP-2, MMP-9, MT1-MMP,
TIMP-1, and TIMP-2 mRNA expression in the renal cell
carcinomas was significantly higher than in the normal
renal tissue (P <0.05). MMP-2, MMP-9, MT1-MMP,
TIMP-1, and TIMP-2 mRNA expression did not differ
significantly in relation to tumor type or pathologic
grade of renal cell carcinoma. MMP-2, MMP-9 and
MT1-MMP mRNA expression increased significantly
with the TNM stage of the tumor.
Several studies have suggested that the role of MMP-2
and MMP-9 in the digestion of basement membrane
type IV collagen is an important mechanism for vessel
invasion and metastasis [6,19]. Because of its ability toTable 4 Expression of matrix metalloproteinases (MMPs) and
type and pathologic grade
Tumor Type
Clear cell Non-clear cell P v
MMP-2 0.741 ± 0.064 0.699 ± 0.078 NS
MMP-9 0.730 ± 0.086 0.623 ± 0.069 NS
MT1-MMP 0.478 ± 0.036 0.393 ± 0.029 NS
TIMP-1 0.369 ± 0.051 0.390 ± 0.034 NS
TIMP-2 0.388 ± 0.029 0.379 ± 0.023 NS
NS, not significant.degrade the basement membrane, MMP-2 has been pos-
tulated to be a potential marker of tumor progression
and prognosis. Gohji et al. [20] reported increased
serum levels of MMP2 in patients with urothelial cancer
that correlated with disease progression and poor out-
come. Kugler et al. [21] analyzed MMP2, MMP9,
TIMP1, and TIMP2 in 17 renal cell carcinomas by PCR
and demonstrated a strong correlation between
increased gene expression and tumor stage. Some
in vivo and in vitro experiments showed that MMP
levels were related to the invading and metastatic poten-
tial of colorectal cancer. Sier et al. [19] demonstrated
that higher tissue levels of total MMPs and the pro-
forms of MMP-2 and MMP-9, as well as the active form
of MMP-2 indicated a poor prognosis in patients with
gastric cancer. Some authors reported that the matrix-
degrading activity of MMP-9 is nearly 25 times that of
MMP-2, and that MMP-9 is more important for the
metastatic potential of carcinoma than MMP-2 [22,23].
Furthermore, MMP-9 expression by immunohistochem-
istry has been found to be significantly correlated with
poor prognosis in renal cell carcinoma [24]. In contrast,
another study showed no significant correlation between
MMP-9 mRNA expression and the prognosis of patients
with hepatocellular cancer. Baseline levels of MMP-9
warrant further study as predictive markers of sunitinib
activity in metastatic renal-cell carcinoma (MRCC) [25].
Porta et al. [26] reported that serum levels of VEGF and
NGAL are significant predictors of progression-freetissue inhibitors of metalloproteinases (TIMPs) by tumor
Pathologic Grade
alue High Low P value
0.722 ± 0.056 0.796 ± 0.095 NS
0.685 ± 0.062 0.749 ± 0.090 NS
0.451 ± 0.042 0.485 ± 0.031 NS
0.394 ± 0.046 0.319 ± 0.040 NS
0.383 ± 0.014 0.395 ± 0.017 NS
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with sunitinib. In our study, mean MMP-2 and MMP-9
mRNA expression in the renal cell carcinomas was signifi-
cantly higher than in the normal renal tissue (P <0.05), the
levels of MMP-2 and MMP-9 mRNA expression were not
correlated with tumor type or pathologic grade of renal cell
carcinoma. MMP-2 and MMP-9 mRNA expression
increased significantly with the TNM stage of the tumor.
MT1-MMP, the first member of a more recently estab-
lished group of MMPs containing a membrane-spanning
sequence, has been shown to have an important role in
MMP-2 activation in cell membranes, and its overex-
pression seems to have a significant effect on tumor
growth. Expression of MT1-MMP mRNA tends to be
associated with a lower degree of differentiation in hepa-
tocellular cancer and has a strong statistical association
with poor prognosis [27]. Moreover, a similar tendency
was also observed in relation to pancreatic adenocarcin-
omas, but the association did not reach statistical signifi-
cance [27]. In addition, Kitagawa et al. [28] showed that
MT1-MMP in particular was associated with invasive-
ness of renal cell carcinoma. In this study, mean MT1-
MMP mRNA expression in the renal cell carcinomas
was significantly higher than in the normal renal tissue
(P <0.01), and the levels of MT1-MMP mRNA expres-
sion were not correlated with tumor type or pathologic
grade of renal cell carcinoma. MT1-MMP mRNA ex-
pression increased significantly with the TNM stage of
the tumor.
In the context of tumor invasion, the original under-
standing of TIMPs was that of an inhibitor of MMPs,
thus serving as anti-invasive/anti-metastatic agents. {AU
Query: Please verify that changes made to the previous
sentence did not alter intended meaning.}TIMPs have
been reported to be negative regulators of MMPs in
mouse tumor models and in humans, in vitro and
in vivo [29]. However, in another study using clinical
samples, the expression of TIMP mRNA was higher in
carcinoma tissues. In studies of various types of carcin-
oma, such as head and neck, colorectal, stomach, and
pancreatic carcinomas, both MMPs and TIMPs were
found to correlate with increased metastatic and invasive
potential of tumor cells [15,30]. Furthermore, TIMP-1
and TIMP-2 expression by immunohistochemistry has
been found to be significantly correlated with poor prog-
nosis in renal cell carcinoma [24]. In the present study,
mean TIMP mRNA expression in the renal cell carcin-
omas was significantly higher than in the normal renal
tissue (P <0.05). et al. [21] and Kallakury et al. [24].
Although both neoplastic and normal cells produce
MMPs and other proteinases, only malignant cells are in-
vasive [31]. Therefore, it is more likely that the control of
MMP activity by specific inhibitors is one cause of the dif-
ferent functions of these enzymes in neoplastic and normaltissues. Ko et al. [32] has reported that TIMP-2 is inversely
correlated with nodal metastasis and that TIMP-2 expres-
sion is stronger in early gastric cancer than in advanced
gastric cancer, indicating that TIMP-2 may play an import-
ant role in protection against MMPs. However, another
study showed that the expression of TIMP-2 was not asso-
ciated with variable clinicopathological parameters, and
that the status of TIMP-2 expression was variable in many
types of cancer tissues. In our study, TIMP-1, and TIMP-2
mRNA expression did not differ significantly in relation to
tumor type, pathologic grade or tumor stage of renal cell
carcinoma.
Conclusions
In summary, mean MMP-2, MMP-9, MT1-MMP, TIMP-1,
and TIMP-2 mRNA expression in the renal cell carcin-
omas was significantly higher than in the normal renal tis-
sue (P <0.05). MMP-2, MMP-9, MT1-MMP, TIMP-1, and
TIMP-2 mRNA expression did not differ significantly in
relation to tumor type or pathologic grade of renal cell
carcinoma. MMP-2, MMP-9 and MT1-MMP mRNA
expression increased significantly with the TNM stage
of the tumor.
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